Qing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qing Li has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Zhong Wang
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
10 shared publications Changhua Zhou
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
5 shared publicationsJing Li
School of Pharmaceutical Sciences, Sun Yat‑sen University, Guangzhou, Guangdong 510006, P.R. China
4 shared publicationsDonglin Cao
Department of Laboratory Medicine, Guangdong Second Provincial General Hospital, Guangzhou, China
3 shared publicationsHong Zhang
School of Pharmaceutical Sciences & Centre for Cellular and Structural Biology of Sun Yat-sen University, Guangzhou, 510006, China
3 shared publicationsJiayu Liu
School of Pharmaceutical Sciences, Sun Yat-Sen University; Center for Cellular & Structural Biology, Sun Yat-Sen University
3 shared publications
Latest Publications
- 24 February 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (7) , 1660-1668
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL.
- 24 February 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (7) , 1660-1668
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL.
- 12 July 2018
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 137
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
A Gpc3-targeting Bispecific Antibody Gpc3-s-fab With Potent Cytotoxicity. JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles. JoVE is the world-leading producer and provider of science videos with the mission to improve scientific research, scientific journals, and education. Millions of scientists, educators and students at thousands of universities, colleges, hospitals and biopharmaceutical companies worldwide use JoVE for their research, teaching and learning.
- 12 July 2018
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 137
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
A Gpc3-targeting Bispecific Antibody Gpc3-s-fab With Potent Cytotoxicity. JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles. JoVE is the world-leading producer and provider of science videos with the mission to improve scientific research, scientific journals, and education. Millions of scientists, educators and students at thousands of universities, colleges, hospitals and biopharmaceutical companies worldwide use JoVE for their research, teaching and learning.
- Open Access
- 11 May 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1) , 1259-1266
A HER2 bispecific antibody can be efficiently expressed in Escherichia�coli with potent cytotoxicity
Bispecific antibodies have been actively studied for cancer therapy due to their potent cytotoxicity against tumor cells. A number of bispecific antibody formats have exhibited strong tumor cytotoxicity in vitro and in vivo. However, effective production of bispecific antibodies remains challenging for the majority of bispecific antibody formats. In the present study, a bispecific antibody was designed that links a conventional antigen-binding fragment (Fab) against cluster of differentiation 3 antigen (CD3) to a camel single domain antibody (VHH) against human epidermal growth factor receptor 2 (HER2). This bispecific antibody may be secreted and purified efficiently from Escherichia coli culture medium. The purified bispecific antibody is able to trigger T cell-mediated HER2-specific cytotoxicity in vitro and in vivo. The data gathered in the present study suggest that this bispecific format may be applied to other tumor antigens to produce bispecific antibodies more efficiently.
- 11 May 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1) , 1259-1266
Open AccessA HER2 bispecific antibody can be efficiently expressed in Escherichia�coli with potent cytotoxicity
Bispecific antibodies have been actively studied for cancer therapy due to their potent cytotoxicity against tumor cells. A number of bispecific antibody formats have exhibited strong tumor cytotoxicity in vitro and in vivo. However, effective production of bispecific antibodies remains challenging for the majority of bispecific antibody formats. In the present study, a bispecific antibody was designed that links a conventional antigen-binding fragment (Fab) against cluster of differentiation 3 antigen (CD3) to a camel single domain antibody (VHH) against human epidermal growth factor receptor 2 (HER2). This bispecific antibody may be secreted and purified efficiently from Escherichia coli culture medium. The purified bispecific antibody is able to trigger T cell-mediated HER2-specific cytotoxicity in vitro and in vivo. The data gathered in the present study suggest that this bispecific format may be applied to other tumor antigens to produce bispecific antibodies more efficiently.
- Open Access
- 1 May 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 3189-3201
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Introduction: Bispecific antibodies that engage immune cells to kill cancer cells are actively pursued in cancer immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab fragments, nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low molecular weight of bispecific antibodies with single-chain or Fab fragments generally leads to their rapid clearance in vivo, which limits the therapeutic potential of these bispecific antibodies. Materials and methods: In this study, we used a site-specific PEGylation strategy to modify the bispecific single-domain antibody-linked Fab (S-Fab), which was designed by linking an anticarcinoembryonic antigen (anti-CEA) nanobody with an anti-CD3 Fab. Results: The half-life (t1/2) of PEGylated S-Fab (polyethylene glycol-S-Fab) was increased 12-fold in vivo with a slightly decreased tumor cell cytotoxicity in vitro as well as more potent tumor growth inhibition in vivo compared to S-Fab. Conclusion: This study demonstrated that PEGylation is an effective approach to enhance the antitumor efficacy of bispecific antibodies.
- 1 May 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 3189-3201
Open AccessSite-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Introduction: Bispecific antibodies that engage immune cells to kill cancer cells are actively pursued in cancer immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab fragments, nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low molecular weight of bispecific antibodies with single-chain or Fab fragments generally leads to their rapid clearance in vivo, which limits the therapeutic potential of these bispecific antibodies. Materials and methods: In this study, we used a site-specific PEGylation strategy to modify the bispecific single-domain antibody-linked Fab (S-Fab), which was designed by linking an anticarcinoembryonic antigen (anti-CEA) nanobody with an anti-CD3 Fab. Results: The half-life (t1/2) of PEGylated S-Fab (polyethylene glycol-S-Fab) was increased 12-fold in vivo with a slightly decreased tumor cell cytotoxicity in vitro as well as more potent tumor growth inhibition in vivo compared to S-Fab. Conclusion: This study demonstrated that PEGylation is an effective approach to enhance the antitumor efficacy of bispecific antibodies.
- Open Access
- 1 April 2018
- Published by Elsevier in Translational Oncology
- Vol. 11 (2) , 366-373
A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
- 1 April 2018
- Published by Elsevier in Translational Oncology
- Vol. 11 (2) , 366-373
Open AccessA Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
- Open Access
- 24 February 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (33) , 23102-23113
A targeted transforming growth factor-beta (TGF-β) blocker, TTB, inhibits tumor growth and metastasis
A targeted transforming growth factor-beta (TGF-) blocker, TTB, inhibits tumor growth and metastasis A Targeted Transforming Growth Factor-beta (TGF-β) Blocker, TTB, Inhibits Tumor Growth and Metastasis.
- 24 February 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (33) , 23102-23113
Open AccessA targeted transforming growth factor-beta (TGF-β) blocker, TTB, inhibits tumor growth and metastasis
A targeted transforming growth factor-beta (TGF-) blocker, TTB, inhibits tumor growth and metastasis A Targeted Transforming Growth Factor-beta (TGF-β) Blocker, TTB, Inhibits Tumor Growth and Metastasis.
- Open Access
- 22 January 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (1) , e0191024
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression. In this study, we employed bispecific antibody approach to target Muc1 positive tumor cells. A novel bispecific antibody, Muc1-Bi-1, was constructed by linking single domain antibodies, anti-Muc1-VHH and anti-CD16-VHH. Muc1-Bi-2, the humanized form of Muc1-Bi-1, was also constructed by grafting. Both Muc1-Bi bispecific antibodies can be efficiently expressed and purified from bacteria. In vitro, the Muc1-Bi bispecific antibodies can recruit Natural Killer (NK) cells to drive potent and specific cell killing of Muc1-overexpressing tumor cells. In xenograft model, the Muc1-Bi bispecific antibodies can suppress tumor growth in the presence of human peripheral blood mononuclear cells (PBMC). These data suggested that the single domain based Muc1-Bi may provide a valid strategy for targeting tumors with Muc1 overexpression.
- 22 January 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (1) , e0191024
Open AccessSingle domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression. In this study, we employed bispecific antibody approach to target Muc1 positive tumor cells. A novel bispecific antibody, Muc1-Bi-1, was constructed by linking single domain antibodies, anti-Muc1-VHH and anti-CD16-VHH. Muc1-Bi-2, the humanized form of Muc1-Bi-1, was also constructed by grafting. Both Muc1-Bi bispecific antibodies can be efficiently expressed and purified from bacteria. In vitro, the Muc1-Bi bispecific antibodies can recruit Natural Killer (NK) cells to drive potent and specific cell killing of Muc1-overexpressing tumor cells. In xenograft model, the Muc1-Bi bispecific antibodies can suppress tumor growth in the presence of human peripheral blood mononuclear cells (PBMC). These data suggested that the single domain based Muc1-Bi may provide a valid strategy for targeting tumors with Muc1 overexpression.
- Open Access
- 1 October 2017
- Published by Elsevier in Translational Oncology
- Vol. 10 (5) , 780-785
BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells
- 1 October 2017
- Published by Elsevier in Translational Oncology
- Vol. 10 (5) , 780-785
Open AccessBiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells
- 13 June 2016
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (10) , 2491-2500
Bispecific antibodies in cancer immunotherapy
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied. Among the various approaches to cancer immunotherapy, 2 bispecific antibodies are currently approved for patient care. Many more bispecific antibodies are now in various phases of clinical development and will become the next generation of antibody-based therapies. Further understanding of immunology and advances in protein engineering will help to generate a greater variety of bispecific antibodies to fight cancer. Here, we focus on bispecific antibodies that recruit immune cells to engage and kill tumor cells.
- 13 June 2016
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (10) , 2491-2500
Bispecific antibodies in cancer immunotherapy
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied. Among the various approaches to cancer immunotherapy, 2 bispecific antibodies are currently approved for patient care. Many more bispecific antibodies are now in various phases of clinical development and will become the next generation of antibody-based therapies. Further understanding of immunology and advances in protein engineering will help to generate a greater variety of bispecific antibodies to fight cancer. Here, we focus on bispecific antibodies that recruit immune cells to engage and kill tumor cells.